Preview: 10x Genomics's Earnings
Portfolio Pulse from Benzinga Insights
10x Genomics (NASDAQ:TXG) is scheduled to release its quarterly earnings report on February 15, 2024, with an estimated EPS of $-0.36. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historical data shows that 10x Genomics has had a mixed performance in beating EPS estimates, with share price reactions varying accordingly. Currently, shares are trading at $46.78, marking a 6.47% decline over the last 52 weeks, indicating a bearish sentiment among long-term shareholders.
February 14, 2024 | 5:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
10x Genomics is anticipated to report its quarterly earnings with an estimated EPS of $-0.36. Investors are looking for an earnings beat and positive future guidance. The stock has seen a 6.47% decline over the past year, indicating bearish sentiment.
The short-term impact on TXG's stock price will likely hinge on whether it beats the EPS estimate and provides optimistic future guidance. Historical performance shows mixed reactions to past earnings, making the short-term direction uncertain. The current bearish sentiment among long-term shareholders could temper any positive reaction unless the earnings significantly exceed expectations.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100